JPMorgan Chase & Co. Grows Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

JPMorgan Chase & Co. raised its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 37.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 58,148 shares of the company’s stock after acquiring an additional 15,706 shares during the quarter. JPMorgan Chase & Co.’s holdings in Structure Therapeutics were worth $1,628,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC increased its position in shares of Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares during the last quarter. State of Wyoming purchased a new stake in shares of Structure Therapeutics during the second quarter worth about $28,000. ANTIPODES PARTNERS Ltd increased its position in shares of Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,146 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Structure Therapeutics by 9.4% during the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after acquiring an additional 413 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Structure Therapeutics during the second quarter worth about $129,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on GPCR shares. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. HC Wainwright dropped their target price on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, March 16th. JPMorgan Chase & Co. lifted their target price on Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. Leerink Partners reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Finally, BMO Capital Markets set a $145.00 target price on Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Structure Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $110.00.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $53.11 on Thursday. The company has a market capitalization of $3.76 billion, a price-to-earnings ratio of -67.23 and a beta of -1.17. Structure Therapeutics Inc. Sponsored ADR has a one year low of $13.22 and a one year high of $94.90. The stock has a 50-day simple moving average of $62.49 and a 200 day simple moving average of $53.25.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). On average, equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.